Greg Hinkle
Alnylam Pharmaceuticals
7 Papers
16 Citations
Greg Hinkle is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Biology & Exome. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
Joseph D. Szustakowski,Suganthi Balasubramanian,Ariella Sasson,Shareef Khalid,Paola G. Bronson,Erika Kvikstad,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeff Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard Jacob,Sándor Szalma,Heiko Runz,Greg Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: Early results from the exome sequence data generated by the UKB-ESC for the first ~200,000 UKB subjects are described and the rationale for the use of human genetics in drug discovery as well as lessons learned are described.
Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals.
Seshu Tummala,Michael Titus,Lee Wilson,Chunhua Wang,Carlo Ciatto,Greg Thill,Donald Foster,Chen Li,Zoltan Szabo,András Guttman,Brian Bettencourt,Muthuswamy Jayaraman,Jack Deroot,David Kocisko,Stuart Pollard,Klaus Charisse,Satya Kuchimanchi,Greg Hinkle,Stuart Milstein,Rachel Meyers,Shiaw Lin Wu,Barry L. Karger,Anthony Rossomando +22 more
TL;DR: It is established that exogenous addition of siRNA represents a potentially novel metabolic engineering tool to improve biopharmaceutical function and quality that can complement existing metabolic engineering methods.
Patent
Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
Anthony Rossomando,Stuart Pollard,John M. Maraganore,Greg Hinkle,Brian Bettencourt +4 more
- 15 Jun 2011
TL;DR: In this paper, the authors provided a transcriptome of a Chinese hamster ovary cell comprising the genes expressed by the CHO cells and a set of siRNAs targeting these transcripts.
11
•Journal Article
Abstract 666: RNAi Therapeutics Targeting Human Angiotensinogen (hAGT) Ameliorate Preeclamptic Sequelae in an Established Transgenic Rodent Model for Preeclampsia
Nadine Haase,Don Foster,Julia Bercher,Stuart Milstein,Michaela Golic,Klaus Charisse,Julianna Rugor,Satya Kuchimanchi,Lukasz Przybyl,Brian Bettencourt,Dominik N. Müller,Greg Hinkle,Ralf Dechend +12 more
TL;DR: The data show that an RNAi therapeutic targeting hAGT ameliorates the clinical sequelae of preeclampsia in a transgenic rat model and improves the outcome of the fetus.
4
Patent
Improving the biological activity of sirna through modulation of its thermodynamic profile
Martin Maier,Haripriya Addepalli,Ligang Zhang,Paul Peng,Muthiah Manoharan,Brian Bettencourt,Greg Hinkle +6 more
- 01 Mar 2011
TL;DR: In this article, the combination of thermally stabilizing and destabilizing chemical modifications and sequence alterations incorporated in specific regions of the duplex to optimize the thermodynamic profile of a given siRNA duplex and to further improve its silencing activity is described.
2